

**MUTATION ANALYSIS OF *PKD1* GENE
IN FAMILIAL POLYCYSTIC KIDNEY DISEASE**

***ANALISIS MUTASI GEN *PKD1* PADA
PENYAKIT GINJAL POLIKISTIK FAMILIAL***



THESIS

**Submitted to fulfill the assignment and fit-out requisite in passing
Post-graduate Program**

Magister of Biomedical Science

**By:
Stefani Harum Sari
NIM: 22010111400102**

**FACULTY OF MEDICINE
DIPONEGORO UNIVERSITY
SEMARANG
2014**

THESIS

**MUTATION ANALYSIS OF *PKD1* GENE
IN FAMILIAL POLYCYSTIC KIDNEY DISEASE**

By:
dr. Stefani Harum Sari
NIM: 22010111400102

Had been defended in front of the defense committee on 3rd May 2014 and has
been approved by:

Principal Supervisor,

Supervisor,

Prof. dr. Sultana MH Faradz, PhD
NIP: 1952 0202 1979 01 2 004

dr. Farmaditya EP Mundhofir, PhD
NIP. 19810425 200812 1 002

Recognition,

Head of Master's Degree Program in Biomedical Science
Post Graduate Program Diponegoro University

Prof. DR. dr. Tri Nur Kristina, DMM, M.Kes
NIP. 195905271986032001

DECLARATION

I hereby declare that this submission is my own work and that, to the best of my knowledge and belief, it contains no material previously published or written by another person nor material which to a substantial extent has been accepted for the award of any other degree or diploma of the university or other institute of higher learning, except where due acknowledgement is made in the text.

Semarang, July 2014

dr. Stefani Harum Sari

CURRICULUM VITAE

Personal Data

Name : Stefani Harum Sari
Sex : Female
Nationality : Indonesian
Place & Date of Birth : Semarang / March 31th, 1988
Latest Degree : Medical Doctor
Address : Karonsih Utara VIII No. 362 Ngaliyan, Semarang,
Central Java, Indonesia, 50192
Mobile phone : +62 813 9040 2525
Email : dr.stefanisari@gmail.com
Civil status : Married

Education

1993-1999 SD Ngaliyan 01 Semarang Elementary School
1999-2002 SLTP N 01 Semarang Junior High School
2002-2005 SMA N 3 Semarang Senior High School
2005-2009 Medical Bachelor Degrees UNDIP (GPA Score : 3,41)
2009-2011 Medical Doctor UNDIP (GPA Score : 3,76)
2011-Present Biomedical Science Majoring in Genetic Counselling
UNDIP

Training/Workshop/Seminar

- 2012 10th Medical Genetic Course: From Basic to Clinic
Faculty of Medicine Diponegoro University, Semarang
- 2012 Workshop on Neurogenetics
Faculty of Medicine Diponegoro University, Semarang
- 2012 Ciliary Dysfunction in Developmental Abnormalities and
Diseases
Faculty of Medicine Diponegoro University, Semarang in
collaboration with Radboud University, Nijmegen.
- 2012 Atrhalgia Case Management: Diagnose, Therapy and
Treatment
Faculty of Medicine UNIMUS, Semarang
- 2014 Medical Genetic Course: From Basic to Clinic
Faculty of Medicine Diponegoro University, Semarang
- 2014 Physical Medicine and Rehabilitation Management in
Musculoskeletal Problems
PESDOSRI of Central Java - DIY
- 2014 Meet the Expert on Infertility
Faculty of Medicine Diponegoro University/RSUP DR.
Kariadi, Semarang

Unpublished Paper

2009 Clinical Variance of Childhood Autism Rating Scale on
Autism in Indonesia

Award/Grant

2007 Third Winner Poster Presentation:
“Geriatric Challenge in Indonesia”
Faculty of Medicine, Udayana University, Bali

2013 Recipient of Research Grant from Risbin IPTEKDOK 2013
Ministry of Health, Indonesia

Works

2007-2008 Student Assistant of Medical Physics Department Faculty of
Medicine Diponegoro University

2008-2009 Student Assistant of Parasitology Department Faculty of
Medicine Diponegoro University

2011-2012 General Practitioner at Maternity Clinics Bhakti Sejahtera,
Semarang

2012-2013 Private General Practitioner at Tentara Pelajar 96, Semarang

2013-present Private General Practitioner at Purwoyoso IB/18, Semarang

ACKNOWLEDGEMENT

It is a pleasure to give my gratitude in honour of to all of persons who gave me input to complete this thesis. I wish to thank my principal supervisor, Prof. dr. Sultana MH Faradz, PhD, for teaching and supervising me about medical genetic, for her encouragement in supporting my thesis especially for guiding me until receive research grant by Risbin IPTEKDOK 2013, Ministry of Health, Indonesia and for her time to support me to finish this study. I would also like to thank my additional supervisor, dr. Farmaditya EP Mundhofir, PhD for his patience in teaching in molecular genetic analysis and guiding me in writing good thesis.

I would like to sincerely express my gratitude to dr. Dwi Lestari P (Internist, Nephrologists) for providing access to PKD patients and their clinical data, for guiding me to establish clinical diagnosis and for being my best partner along this study. Thank you for her families which also going along with us when home-visits. Thank you to dr. Hermina S (Radiologist) for giving ultrasound examination and also her expertises on PKD criteria.

I wish to express my special gratitude to dr. Ferdy K Cayami, MSc and dr. Dian Mayasari AA, MSi.Med for mentoring me in qPCR-HRM technique. I would also like to thank all the staff of CEBIOR, particularly to Wiwik Lestari, Dwi Kustiani, Efi, Lusi Suwarsi, Rita Indriati and Intus Apriasa for laboratory assistance during my study.

Thank you for Batch 6 students of Masters in Biomedical Science, Hesty Wahyuningsih, Isna Rahmia Fara, Donny Nauphar, Almira Zada, Venty Muliana Sari, Ariestya Indah PS, Gara Samara Bradjadenta, Ziske Maritska and Zukhrofi Muzar. Your help and support has been a source of my inspiration. My utmost gratitude to my parents, Sadiman Al Kundarto and Isti Widiastuti; to my husband, Imam Yugo Santoso and my little daughter, Tsabita Yuri Equatra, who have been my spirit and strength during my study.

Thank you for the reviewer, dr. RA Kisdjamiatun, MSc, PhD for all the correction and advice for my thesis. This opportunity to join the master degree, to do the research would not have been possible without the fellowship from Biro Perencanaan Kerjasama Luar Negeri (BPKLN), Ministry of Education, Indonesia, especially for DR. AB Susanto, MSc as Beasiswa Unggulan coordinator. I wish to thank Risbin Iptekdok 2013, Ministry of Health, Indonesia for supporting funding and also initial review to my study. My grateful to all of the master degree and fellowship coordinators, especially to Prof. dr. Sultana MH Faradz, PhD; DR. dr. Tri Indah Winarni, MsiMed; Ms. Ardina Aprilani, SSos and dr. Farmaditya EP Mundhofir, Phd. I am deeply thankful for your hardworks.

CONTENTS

SHEET OF TITLE	i
SHEET OF APPROVAL	ii
DECLARATION	iii
CURRICULUM VITAE	iv
ACKNOWLEDGEMENT	vii
TABLE OF CONTENTS	ix
ABBREVIATIONS	xiii
GLOSSARIES	xv
LIST OF TABLES	xvii
LIST OF FIGURES	xviii
LIST OF APPENDICES	xix
ABSTRACT (ENGLISH)	xx
ABSTRACT (BAHASA INDONESIA)	xxi
CHAPTER I. INTRODUCTION	1
1.1 Background	1
1.2 Research Questions	2
1.3 Research Objectives	3
1.3.1 General Objectives	3
1.3.2 Specific Objectives	3
1.4 Research Advantages	3
1.5 Originality	3

CHAPTER II. LITERATURE REVIEW	5
2.1 Polycystic Kidney Disease	5
2.2 Epidemiology	6
2.3 Pathogenesis of ADPKD	7
2.3.1 <i>PKDI</i> Gene Mutation	7
2.3.2 Cyst Formation	8
2.3.2.1 Ciliopathy on ADPKD	9
2.3.2.2 Intraepithelial Fluid Secretion	11
2.3.2.3 Hypothesis of Second-Hit Mutation	14
2.4 Disease Manifestations	15
2.5 Diagnosis	18
CHAPTER III. THEORETICAL AND CONCEPTUAL SCHEME	21
3.1 Theoretical Scheme	21
3.2 Conceptual Scheme	21
CHAPTER IV. RESEARCH METHODS	22
4.1 Research Aspects	22
4.1.1 Field	22
4.1.2 Location	22
4.1.3 Period	22
4.1.4 Design	22
4.2 Materials	22
4.2.1 Population	22
4.2.2 Samples	23

4.2.2.1	Inclusion Criteria	23
4.2.2.2	Exclusion Criteria	23
4.2.2.3	Subject Selection	23
4.2.2.4	Subject Estimation	23
4.3	Methods	24
4.3.1	General	24
4.3.2	Physical Examination	24
4.3.3	Laboratory Methods	24
4.3.3.1	Blood aspiration	24
4.3.3.2	DNA extraction	24
4.3.3.3	<i>PKD1</i> Gene Mutation Identification	25
4.4	Variables	27
4.5	Operational definitions	28
4.6	Data Analysis	30
4.7	Research Ethics	31
4.8	Research Flow	32
	CHAPTER V. RESULTS	33
5.1	Sample Characteristics	33
5.2	Pedigree Analysis	35
5.3	Mutation Analysis	37
5.4	Genotype - Phenotype Correlation	41
5.5	Benefit of qPCR-HRM in <i>PKD1</i> Identification	44

CHAPTER VI. DISCUSSION	45
CHAPTER VII. CONCLUSION AND FUTURE DIRECTIONS	55
CHAPTER VIII. SUMMARY	57
REFERENCES	60
APPENDICES	64

ABBREVIATIONS

ADPKD	Autosomal Dominant Polycystic Kidney Disease
<i>AQP</i>	Aquaporin
ARPKD	Autosomal Recessive Polycystic Kidney Disease
CACC	Ca ²⁺ activated Cl ⁻ channel
cAMP	Cyclic Adenosin Monophosphate
<i>CFTR</i>	Cystic Fibrosis Trans-membrane Regulator
EGF	Epidermal Growth Factor
ER	Endoplasmic Reticulum
ESRD	End Stage Renal Disease
GCKD	Glomerulocystic Kidney Disease
NKCC1	Na ⁺ /K ⁺ /2Cl ⁻ cotransporter1
HNFB1	Hepatocyte nuclear factor 1, homeobox B
HRM	High Resolution Melting
IPR3	Inositol Triphosphate Receptor
PC1	Polycystin1
PC2	Polycystin2
PCP	Planar Cell Polarity
PCR	Polymerase Chain Reaction
qPCR	Quantitative or Qualitative Polymerase Chain Reaction
PDE	Phosphodiesterase
PI	Proliferation Index

PKA	Protein Kinase-A
PKD	Polycystic Kidney Disease
<i>PKD1</i>	Polycystic Kidney Disease1
<i>PKD2</i>	Polycystic Kidney Disease2
RyR	Ryanodine Receptor
SERCA	Sarco (Endo)Plasmic Reticulum Ca ²⁺ ATP ase
SIFT	Sorting Intolerant From Tolerant
SNP	Single Nucleotide Polymorphism
SST2	Somatostatin Receptor2
T _m	Temperature Melting
TNF- α	Tumor Necrosis Factor Alpha
TRP	Transient Receptor Potential Channel
TRPP	Transient Receptor Potential Polycystin Channel
<i>TSC2</i>	Tuberous Sclerosis2
UROM	Uromodulin
V2R	Vasopressin2 Receptor

GLOSSARIES

ADPKD	genetically heterogeneous, with mutations of 2 genes (PKD1 and PKD2) responsible for most cases.
Align-GVGD	a freely access website program to predict missense substitutions whether pathogenic or not. This program analyzes the biophysical characteristics of amino acids and protein multiple sequence alignments to predict missense substitutions in genes of interest fall in a spectrum from enriched deleterious to enriched neutral.
Cyst	an abnormal structure of tissue which is formed closed sac-like, containing a liquid, gaseous or semisolid substance. Outer membrane of the cyst, the cyst wall, differentiates this structure to the nearby tissue.
CKD	abnormalities of kidney structure or function, present for 43 months, with implications for health.
ESRD	a continuum of CKD, is defined as irreversible kidney failure treated with dialysis or transplantation.
HRM	a post-PCR method to analyze genetic variations (SNPs, mutations, methylations) in PCR amplicons. HRM is good screening method to analyze variations in PCR amplicons before establishment of definit diagnosis using sequencing.
PCR	a biochemical technology in molecular biology based on using the ability of DNA polymerase to amplify a single or few copies of a spesific region of DNA. The result of PCR reaction is thousand to million copies of a particular DNA sequence.
qPCR	a method part of method in Real Time-PCR which is used to amplify and simultaneously detect or quantify a targeted DNA molecule. In qualitative qPCR, the goal is to detect the presence or absence of a certain sequence, allelic discrimination between

wild type and mutant, between different SNPs or between different splicing forms.

SIFT predicts whether an amino acid substitution affects protein function based on sequence homology and the physical properties of amino acids.

Mutation taster a free web-based application for rapid evaluation of the disease-causing potential of DNA sequence alterations. MutationTaster integrates information from different biomedical databases and uses established analysis tools (Supplementary Methods). Analyses comprise evolutionary conservation, splice-site changes, loss of protein features and changes that might affect the amount of mRNA. Test results are then evaluated by a naive Bayes classifier, which predicts the disease potential.

LIST OF TABLES

Table 1. Research originality	4
Table 2. Classification of PKD	5
Table 3. Ravine ultrasonographic criteria for diagnosing ADPKD	17
Table 4. Classification of SNPs change in the human genome	20
Table 5. Reaction steps of RT-PCR HRM for <i>PKD1</i> gene amplification	26
Table 6. JNC VII criteria for blood pressure classification	30
Table 7. Sample characteristics	33
Table 8. Blood pressure status in group of clinical diagnosis	34
Table 9. Clinical profile of PKD samples	35
Table 10. Pedigree analysis	36
Table 11. Family history of diseases	36
Table 12. Amplicons obstacles in qPCR-HRM amplification	37
Table 13. Missense mutation	38
Table 14. Synonymous mutation	39
Table 15. Variants distribution at samples	39
Table 16. Genotype changes and clinical phenotypes	42
Table 17. Duration of qPCR-HRM cycles	44

LIST OF FIGURES

Figure 1. Mutation distribution in <i>PKD1</i> gene	8
Figure 2. The schematic picture of primary cilium in renal epithelial cells ...	10
Figure 3. Schematic view of intraepithelial fluid transport in ADPKD cyst ..	13
Figure 4. Possibility genotyping by HRM analysis	19
Figure 5. Mutation screening in exon 5C	40
Figure 6. Mutation screening in exon 45	41
Figure 7. Mutation screening in exon 4	46
Figure 8. Forward sequence showed variants in samples 10.3/S/13	47
Figure 9. Mutation screening in exon 6	49

LIST OF APPENDICES

Appendix 1. Ethical Clearance	64
Appendix 2. Informed Consent	65
Appendix 3. Clinical Data of patients	68
Appendix 4. Crosstabs Blood Pressure Status and Clinical Diagnosis	70
Appendix 5. Pedigrees	71
Appendix 6. Primer qPCR-HRM for <i>PKD1</i> Gene Identification	76
Appendix 7. Setting qPCR-HRM and problems	80

ABSTRACT

Background: Polycystic kidney disease (PKD) is a genetic disorder. The replacement of normal structure with numerous cysts is potential leading to renal failure. PKD contributed to 2.51% end stage renal disease (ESRD) in Indonesia, but its genetic base has been unknown. The most common form of PKD is autosomal dominant polycystic kidney disease (ADPKD). Mutation in *PKDI* gene is found in the most of ADPKD cases (85%). Pre-screening molecular diagnostic step is useful to minimize the complexity of mutation analysis in *PKDI* gene.

Methods: DNA samples from 27 patients were collected from 13 index families. Fourty six exons of *PKDI* gene were amplified in 59 fragments. qPCR-High Resolution Melting (HRM) analysis was utilized as pre-screening diagnosis steps. Afterwards, variant samples which had aberrant pattern were sequenced.

Results: The clinical evidence of highly suggested familial *PKDI* was found in 6 (46.1%) families. Clinical diagnosis of PKD had associated to hypertension (p -value: 0.045). The amplification was successfully done in 36(61%) amplicons, the remaining 23(39%) amplicons still need to be optimized. Seven variants were identified, in which four variants previously described in literature (c.1001C>T, c.1140C>T, c.1142G>T, c.12276A>G) and three newly described by this study. The new variants were missense mutation (c.1021G>A and c.1240C>T) and synonymous mutation (c.1161C>T). All new variants were predicted as non pathogenic. Two PKD samples from one family was found to carry variant of c.1001 C>T which predicted as likely pathogenic.

Conclusion: Clinical diagnosis of PKD had associated to hypertension (p -value: 0.045). There were 7 variants of *PKDI* gene identified in this study. The identification of pathogenic mutation for *PKDI* gene has not been completed yet. Further optimization at qPCR-HRM method and mutation confirmation study in healthy control are needed.

Keywords: *PKDI* gene, qPCR-HRM analysis, Indonesia

ABSTRAK

Latar Belakang: Penyakit ginjal polikistik (PGP) merupakan suatu kelainan genetik. Perubahan struktur ginjal digantikan dengan struktur kista multipel dapat menyebabkan gagal ginjal. PGP menyumbang 2,51% gagal ginjal terminal (GGT) di Indonesia, namun latar belakang genetik yang mendasari belum diketahui. Jenis PGP yang paling sering ditemukan adalah penyakit ginjal polikistik dominan autosomal (PGPDA). Mutasi pada gen *PKD1* ditemukan pada sebagian besar kasus ADPKD (85%). Penerapan metode diagnosis pre-skrining diharapkan dapat membantu mengatasi kompleksitas analisis mutasi pada gen *PKD1*.

Metode: Sampel DNA dari 27 pasien dikumpulkan dari 13 keluarga indeks. Gen *PKD1* memiliki 46 ekson yang diamplifikasi dalam 59 fragmen. qPCR-HRM digunakan sebagai metode pre-skrining pada diagnosis molekuler. Sekuensing dilakukan pada sampel yang memiliki pola grafik yang berbeda.

Hasil: Kecenderungan adanya pewarisan gen *PKD1* familial secara klinis didapatkan pada 6(46,1%) keluarga. Diagnosis klinis PKD memiliki hubungan dengan hipertensi (*p-value*: 0.045). Amplifikasi berhasil dilakukan pada 36(61%) ampikon, sebanyak 23(39%) sisanya masih memerlukan tahap optimasi lanjut. Terdapat 7 varian yang ditemukan dalam penelitian ini. Empat varian telah dilaporkan pada studi sebelumnya (c.1001 C>T, c.1140 C>T, c.1142 G>T, c.12276A>G) dan 3 varian dilaporkan pertama kali oleh penelitian ini. Klasifikasi mutasi pada varian baru meliputi mutasi *missense* (c.1021G>A and c.1240C>T) dan mutasi sinonim (c.1161C>T). Semua varian diprediksi sebagai non patogenik, kecuali varian c.1001C>T yang diprediksi patogenik pada 2 sampel dari satu keluarga.

Kesimpulan: Diagnosis klinis PKD memiliki hubungan dengan hipertensi (*p-value*: 0.045). Terdapat 7 varian yang ditemukan pada identifikasi mutasi gen *PKD1*. Identifikasi mutasi pada gen *PKD1* belum selesai sepenuhnya. Optimasi lanjut pada metode qPCR-HRM dan studi konfirmasi mutasi pada kontrol sehat masih diperlukan.

Kata kunci: gen *PKD1*, analisis qPCR-HRM, Indonesia